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Abstract
Objective—To examine the effects of GSTM1 null-allele polymorphism on oxidative stress and
disease progression in HIV infected and HIV/hepatitis C (HCV) co-infected adults.
Methods—HIV-infected and HIV/HCV co-infected participants aged 40–60 years old with CD4
cell count >350 cells/ µl, were recruited. GSTM1 genotype was determined by quantitative PCR.
Oxidative stress (mitochondrial 8-oxo-2’-deoxyguanosine [8-oxo-dG], malondialdehyde [MDA],
oxidized glutathione and Complexes I and IV), apoptosis and HIV disease (CD4 count and viral
load) markers were measured. Gene copies were not quantified, thus the Hardy-Weinberg formula
was not applicable.
Results—Of the 129 HIV-infected participants, 58 were HIV/HCV co-infected. GSTM1
occurred in 66% (62/94) in those of African descent, and 33% (11/33) of the Caucasians. Those
with GSTM1 coding for the functional antioxidant enzyme Glutathione S-transferase (GST), had
higher CD4 cell count (β=3.48, p=0.034), lower HIV viral load (β=−0.536, p=0.018), and lower
mitochondrial 8-oxo-dG (β=−0.28, p=0.03). ART reduced oxidative stress in the participants with
the GSTM1 coding for the functional antioxidant enzyme. HIV/HCV co-infected participants with
the GSTM1 coding for the functional antioxidant enzyme also had lower HIV viral load, lower 8-
oxo-dG and lower rate of apoptosis, but also higher oxidized glutathione. Alcohol consumption
was associated with lower HIV viral load but higher oxidized glutathione in those with the
GSTM1 genotype coding for the functional antioxidant enzyme.
Conclusion—The GSTM1 genotype coding for the functional antioxidant enzyme is associated
with lower HIV disease severity, and with lower oxidative stress, compared to GSTM1 null-allele
polymorphism. HCV co-infection and alcohol use may be associated with increased oxidative
stress even in the presence of the GSTM1 coding for the functional antioxidant enzyme. The null-
gene, on the contrary, appears to have a detrimental effect on immune function, viral load control,
and antioxidant status, suggesting a potential benefit from antioxidants in HIV infected patients
with the defective gene.
Copyright: © 2013 Parsons M, et al.
*Corresponding author: Marianna K Baum, Florida International University, R. Stempel College of Public Health and Social Work,
11200 SW 8th Street, Room AHC-1-337, Miami, Florida 33199, Tel: 305-348-2871; Fax: 305-348-0383; baumm@fu.edu.
NIH Public Access
Author Manuscript
J AIDS Clin Res. Author manuscript; available in PMC 2014 January 10.
Published in final edited form as:
J AIDS Clin Res. ; 4(9): . doi:10.4172/2155-6113.1000237.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
GSTM-1 polymorphism; HIV disease progression; Oxidative stress; HIV/HCV co-infection;
Alcohol consumption
Introduction
Mitochondrial damage is implicated in the etiology of complications of chronic human
immunodeficiency virus (HIV) infection, as well as some adverse effects associated with
antiretroviral therapy (ART) [1]. Mitochondrial dysfunction and accumulation of damaged
mitochondrial DNA is also associated with several diseases of aging, including cancer [2]
and is implicated in metabolic, renal, bone, and neurocognitive abnormalities occurring in
patients with HIV [3–7]. Elevated oxidative stress increases the rate of mitochondrial DNA
damage; in turn, accumulation of mitochondrial DNA (mtDNA) mutations further increases
oxidative stress as well as cell apoptosis [2]. The HIV virus activates mitochondrial enzymes
that lead to mitochondrial dysfunction and apoptosis of cells [8,9], including those of the
immune system, such as CD4+ and CD8+ T cells [10]. Increased levels of markers of
oxidative stress including oxidized glutathione, malondialdehyde (MDA), 8-oxo-2’-
deoxyguanosine (8-oxo-dG), as well as the enzyme activity of electron transport chain
enzymes Complex I and Complex IV [1,11–13], decreased antioxidants [14], and
dysregulation of the mitochondrial transmembrane potential [15] have been observed in HIV
infection and HIV/hepatitis C (HCV) co-infection [13–18]. This imbalance in the redox
system has been associated with stimulation of viral replication via activation of nuclear
factor κB and induction of apoptosis of CD4+ T-cells [13,19].
Glutathione-S-Transferases (GSTs) make up a family of phase II detoxification enzymes in
the mitochondria and cytosol, responsible in part for response to oxidative stress in humans.
The GST family includes a diverse range of enzymes; while they differ in their function,
activity, and distribution, they all contribute to detoxification by catalyzing the oxidation of
glutathione, a key intracellular antioxidant molecule [20]. Although, many genes code for
GST enzymes, the gene GSTM1, which encodes a cytosolic GST of the mu subfamily, has
been observed to be highly polymorphic [21]. A common polymorphism involving this gene
prevents transcription of a functional copy of the mu 1 GST enzyme. This GSTM1 “null
allele,” when inherited homozygously, results in absent enzyme activity [22]. Recent studies
have suggested that null genotype of GSTM1 may be associated with risk of cancer and
other diseases related to oxidative stress; individuals with GSTM1 null allele polymorphism
have been observed to be at greater risk for cancers of the breast, prostate, cervix, skin, and
mouth, as well as atopic asthma [22–27].
Although deletion of GSTM1 has been identified as a risk factor for diseases of oxidative
stress, and oxidative stress is implicated in the progression of HIV/AIDS, the effects of
GSTM1 null allele polymorphism in HIV-infected populations are currently unknown. The
primary objective of this investigation was to determine whether homozygous deletion of
GSTM1 will affect oxidative stress levels and disease progression in HIV-infected and HIV/
HCV co-infected individuals.
Methods
Study participants
A cohort of HIV infected participants, consecutively enrolled, was recruited to participate in
this study in Miami, Florida, between February 2009 and August 2012. Participants were
40–60 years old, with CD4 cell count >350 cells/µl, and were HIV infected or HIV/HCV
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coinfected. Participants, who were HBV or HCV mono-infected, or HIV/ HBV co-infected,
were excluded. By using a narrow age range, and CD4 count >350 cells/µl as an inclusion
criteria, conditions previously found to be associated with elevated oxidative stress, i.e.
aging [28] and low CD4 cell count [29], were excluded. The Institutional Review Board of
the Florida International University (FIU) approved the study.
After providing consent, the participants were screened for eligibility, and underwent an
assessment interview that included demographic, substance abuse and medical
questionnaires. Weight and height were obtained in participants wearing light clothing and
no shoes utilizing standard procedures. Body Mass Index (BMI) was calculated using the
standard formula that divides the weight in Kg by the square of the height in meters (Kg/
m2).
Physical examination was completed and anthropometries were measured at the Borinquen
Family Healthcare Center/ FIU Research Clinic in Miami, Florida. HIV, HBV and HCV
status, CD4+ cell count, and HIV viral load, were obtained from the participants’ medical
charts with their consent. Fasting blood was drawn to determine genotypes for GSTM1 allele
polymorphism and to obtain markers of oxidative stress (percent plasma oxidized
glutathione, peripheral blood mononuclear lymphocyte (PBMC) mitochondrial 8-oxo-dG,
malondialdehyde (MDA), Complex I and IV enzyme activity, and apoptosis.
The genotypes for GSTM1 null allele polymorphism were determined from DNA extracted
from PBMC using QIAamp DNA mini kits (Qiagen; Valencia, CA). The presence or
absence of the GSTM1 allele was determined using quantitative PCR (qPCR) based on the
protocol described by Rose-Zerilli et al. [30]. The assay consisted of Taqman minor groove-
binding hydrolysis probes targeting both GSTM1 and ALB (albumin) as a reference gene,
performed in duplicate multiplex wells. Each 25 µl reaction volume contained 2 µl DNA at 5
ng/µl concentration, 12.5 µl 2X iQSupermix (Bio-Rad; Hercules, CA), GSTM1 primers
(0.75 µl forward, 5’ GACTCTTGCATCCTGCACACA 3’, and 1.13 µl reverse, 5’
GGAAAGCACTTGGAGGATGAAT 3’), ALB primers (1.13 µl forward, 5’
CTGTCATCTCTTGTGGGCTGTAA 3’, and 0.75 µl reverse, 5’
GGCATGACAGGTTTTGCAATATT 3’), Taqman MGB probes (0.19 µl GSTM1, 6FAM-
TGGTCTTAAGTCCCTGGTACMGB-NFQ, and 0.19 µl ALB, TET-
CATCGTCTAGGCTTAAGAGMGB-NFQ), and PCR-grade water to achieve the proper
volume. Thermal cycling was performed using an iQ5 qPCR machine (Bio-Rad; Hercules,
CA). Samples underwent a thermal profile of 10 minutes incubation at 95°C, preceding 40
cycles of 15 seconds at 95°C and 60 seconds at 60°C. The amplification plots were analyzed
manually to compare detection of the target sequence to the reference gene. Genotyping
results were validated by inclusion of positive control samples from the ECACC Human
Random Control DNA Panel (Sigma-Aldrich, St. Louis, MO).
Percent oxidized glutathione was determined with the Glutathione Colorimetric Detection
Kit from Arbor Assays (Ann Arbor, MI), using an EL-800 micro-plate reader (Bio-Tek;
Winooski, VT). The MDA protocol was performed with kits purchased from Northwest Life
Science Specialties (Vancouver, WA) using a model DU-530 spectrophotometer by
Beckman-Coulter, Inc. (Indianapolis, IN). Levels of mitochondrial 8-oxo-dG were
determined by qPCR using a standard protocol measured with the iQ5 qPCR system.
Complex I and IV activities were measured using an immuno-chromato-dipstick assay in an
MS1000 immuno-chromato reader by Mitosciences Inc. (Eugene, OR). Epithelial cell
apoptosis was measured by plasma levels of caspasecleaved cytokeratin (CK-18),
determined by M30 Apoptosense ELISA kit (PEVIVA, Bromma, Sweden).
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Statistical analysis
All analyses were performed with SAS version 9.2, using a significance level of P=0.05.
Descriptive statistics were used to characterize the population in terms of mean values for
demographic and anthropometric variables, including sex, age, income, BMI, and waist/hip
ratio. Analysis of Hardy-Weinberg equilibrium was not possible because the genotyping
protocol was unable to differentiate GSTM1 as heterozygotes or wild-types. To normalize
distribution of disease progression variables, HIV viral load was log transformed, and the
square root was taken for CD4 cell count. Multivariate linear regression analyses were used
to compare the binary variable of GSTM1 status with all continuous variables reflecting
oxidative stress (percent oxidized glutathione, mitochondrial 8-oxo-dG, MDA, and Complex
I and IV enzyme activity), apoptosis and disease progression (CD4 count and HIV viral
load). These analyses were performed among the full sample, as well as between the two
sub-cohorts (HIV/HCV co-infected individuals and alcohol users). Age- and gender-
adjusted linear regression models were constructed to assess association of each of the
following possible clinical correlates individually: CD4 cell count, HIV viral load, percent
oxidized glutathione, MDA, mitochondrial 8-oxo-dG, Complex I and IV enzyme activity
and apoptosis, compared the population with the GSTM1 genotype coding for the functional
antioxidant enzyme with those with the null GSTM1 genotype. The parameters generated by
these analyses include all available observations of each given variable among study
participants belonging to the designated cohort or sub-cohort. The analyses for the oxidative
stress were performed on values of individuals who had BMI <28 Kg/m2 and were adjusted
for ART, liver disease, race, drug use and education. Separate analyses were performed with
ART as an independent variable and HIV disease progression, oxidative stress and apoptosis
as dependent variables to determine the contribution of ART on the effects of the GSTM1
genotype.
Results
There were a total of 129 HIV infected participants in the study, 58 (45%) were HIV/HCV
co-infected; qPCR analysis identified 53 (41.2%) of the individuals as null GSTM1, and 76
(58.8%) with GSTM1 coding for the functional antioxidant enzyme. The population
characteristics of the study participants are shown in Table 1. The sample was 56% male and
44% female, with a mean age of 48.32 ± 6.31 years. Mean values for BMI and waist/hip
ratio were 28.29 ± 5.29 Kg/m2 and 0.91 ± 0.07, respectively. Mean CD4 count was 591 ±
414 cells/µL and mean HIV viral load was 16,416 ± 94,636 copies/ml. Genotype frequency
significantly differed based on race, as seen in Figure 1, among the 94 participants of
African descent, 66% possessed the GSTM1 genotype coding for the functional antioxidant
enzyme, while this genotype was observed in only 33% of the 35 Caucasian participants (p=
0.002).
There were no differences in other demographic variables between the participants who had
the null vs. the GSTM1 genotype that codes for the functional antioxidant enzyme.
Table 2 shows the mean and standard deviations for the biomarkers of HIV disease
progression, and Table 3 the measures of oxidative stress associated with the GSTM1
genotype coding for the functional antioxidant enzyme when compared to those who had the
null GSTM1 gene. T-test analyses showed that HIV viral load and the Complex I activity
was significantly lower in the participants with the GSTM1 genotype coding for the
functional antioxidant enzyme (not shown in the tables). When regression analysis was used
to determine the effect of the GSTM1 status and the continuous variables reflecting HIV
disease progression and oxidative stress, several significant relationships were revealed, as
shown in Tables 2 and 3. Participants with the GSTM1 gene coding for the functional
antioxidant enzyme had lower viral load (β=−0.536, p=0.018), and higher CD4 cell count
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(β=3.480, p=0.034), compared to those who had the null GSTM1 gene. Since obesity
profoundly affects oxidative stress [31], only the values for participants with BMI <28 kg/
m2 were used in the analyses when the biomarkers of oxidative stress were considered.
Participants with the GSTM1 genotype coding for the functional antioxidant enzyme had
lower levels of mitochondrial 8-oxo-dG (β=−0.28, p=0.030) than participants with the null
GSTM1 genotype. When ART was used as an independent variable, those with the GSTM1
genotype coding for the functional antioxidant enzyme had lower MDA (β=−1.67, p=0.050),
lower percent oxidized glutathione (β=−5.59, p=0.047), and lower Complex I (β=−13.83,
p=0.040), but higher 8-oxo-dG (β=0.28, p=0.050, results not shown in the tables).
Tables 4 and 5 show the regression coefficients for the effect of the GSTM1 genotype on
HIV disease progression and oxidative stress parameters in the two sub-cohorts. Participants
with HIV/HCV co-infection with the GSTM1 genotype coding for the functional antioxidant
enzyme (Table 4) had significantly lower HIV viral load (β=−0.918, p=0.022), lower
mitochondrial 8-oxo-dG (β=−0.48, p=0.028), and lower rate of apoptosis (β=−67.40,
p=0.009), but they also had higher oxidized glutathione (β=10.02, p=0.028) compared to
those who had the null GSTM1 gene. The participants with the GSTM1 genotype coding for
the functional antioxidant enzyme who consumed alcohol (Table 5) also had lower HIV
viral load (β=−0.789, p=0.027), lower Complex I enzyme activity (β=−16.909, p=0.042), but
significantly higher oxidized glutathione (β=10.63, p=0.029) compared to those who had the
null GSTM1 gene. The GSTM1 genotype did not appear to affect the levels of MDA in any
of the analyses.
In addition to the multivariable analyses to determine whether the GSTM1 genotype affects
markers of HIV disease progression and oxidative stress, we also conducted analyses to
characterize the potential impact of the GSTM1 genotype on disease progression and
oxidative stress among those who are HIV/HCV co-infected and those who consume
alcohol. We compared HIV mono-infected and HIV/HCV co-infected participants and
excluded those who drank alcohol (N=41). The analyses showed that the only variable that
was significantly different between the two groups was hepatocyte apoptosis (β=46.15,
P=0.015), which maintained significance after controlling for age, gender and the null
GSTM1 genotype (β=41.69, P=0.022). Comparison of HIV mono-infected participants who
did or did not consume alcohol showed that the only variable that was significantly
associated with alcohol consumption was hepatic apoptosis (β=33.43, P=0.049); this
relationship however, lost significance when controlled for age, gender and the null GSTM1
genotype showing that the GSTM1 genotype was more important in determining apoptosis
than alcohol consumption.
Discussion
The results of this study indicate that the GSTM1 genotype that codes for the functional
antioxidant enzyme is not equally distributed by race, occurring in 33% of the Caucasians
and 66% of the participants of African descent. The GSTM1 genotype coding for the
functional antioxidant enzyme was associated with more advantageous oxidative stress
status, lower rate of apoptosis, and an apparent favorable effect on both immune function
and viral load control in HIV-infected individuals. ART reduced oxidative stress in
participants with the GSTM1 genotype coding for the functional antioxidant enzyme. HCV
status and alcohol use affected the association of the GSTM1 genotype with oxidative stress,
with both HCV co-infection and alcohol use increasing the levels of oxidative stress in this
cohort.
Glutathione-S-transferases (GSTs) play a role in the detoxification of the reactive oxygen
species [20]. The GSTM1 null-allele polymorphism is associated with reduced
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mitochondrial enzyme activity, decreased ability to detoxify compounds, increased level of
reactive oxygen species, and increased risk of cancers [32–34], diabetes mellitus [35], and
other diseases of aging [2,23–27], primarily among Caucasians [34]. While individual
glutathione-S-tranferase polymorphisms influence vulnerability to oxidative stress, GSTM1-
null gene variant has the most pronounced effect [36]. Only one study was conducted in an
HIV infected population to the best of our knowledge to date, investigating a decreased
response to ART in smoking HIV infected women. This study, however, showed that
GSTM1 deletions were not associated with the effectiveness of the treatment in smokers
[37]. Increased levels of oxidative stress in HIV infected patients, relative to healthy
subjects, have been demonstrated [13–18]. However, the possible effect of the GSTM1
genotype has not been investigated in association with the progression of HIV disease or
oxidative stress variables.
Our results show that the GSTM1 gene coding for the functional antioxidant enzyme
appears to play a role in the defense system against HIV infection, since HIV viral load was
significantly and consistently lower in participants with the GSTM1 genotype that codes for
the functional antioxidant enzyme. Moreover, the lower levels of HIV viral load were
independent of the higher oxidative stress found in HIV/ HCV co-infected participants, and
in those who consumed alcohol. In addition, CD4 count was significantly higher in the
participants with the GSTM1 genotype coding for the functional antioxidant enzyme. The
mechanisms of how the functional antioxidant enzyme confers better protection for HIV
disease severity is not known at this time; our studies with antioxidants [18,38,39] and those
of others [40,41] indicate that, while the primary effect may be on the viral burden, the
observed benefit on CD4 cell count is consistent, with previous studies showing a direct
relationship between serum antioxidants and CD4 cell count [42,43], opportunistic
infections, disease progression, and HIV-related mortality [44–46]. In addition, there
appears to be a disadvantage of reduced detoxification in GSTM1-null individuals that may
promote HIV disease progression.
Alterations of the level of oxidative stress or the redox balance of cells may have major
implications for normal function of cells, and therefore, it is important to consider each
biomarker of oxidative stress in order to determine the overall relationship of GSTM1 null-
allele polymorphism. Since a number of studies have shown associations between increased
oxidative stress, obesity [47,48], insulin resistance [49], and liver disease [50,51], only the
values for participants without diabetes, whose BMI was <28 kg/m2, and adjusted for liver
disease, were used in the analysis considering oxidative stress. Increased levels of
mitochondrial 8-oxo-dG reflect the effect of increased oxidative stress on mitochondrial
DNA, with 8-oxo-dG as one of the major products of mitochondrial DNA oxidation [1].
Thus, the significantly lower levels of mitochondrial 8-oxo-dG in participants with GSTM1
genotype coding for the functional antioxidant enzyme indicate the important advantage
conferred in the defense against DNA damage. The reduced oxidative stress levels
associated with lower 8-oxo-dG may contribute to the favorable effects on disease
progression experienced by individuals with GSTM1 coding for the functional antioxidant
enzyme. The observed lack of association of GSTM1 genotype with MDA, a product of
oxidative damage resulting in lipid peroxidation, is consistent with reported results in other
conditions, including diabetes [52,53], renal disease [36], and coronary artery disease [54],
suggesting that this polymorphism has an insignificant effect on lipid peroxidation in
chronic disease states.
Glutathione, an antioxidant found in all cells, prevents damage caused by oxidative stress;
levels of oxidized glutathione reflect oxidative damage associated with chronic
inflammatory response in HIV infected populations [13]. The results of this study showed
increased percent oxidized glutathione in the HIV/HCV co-infected cohort and in
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participants who consumed alcohol in the presence of lower 8-oxodG, and apoptosis
indicating lower oxidative stress in participants with
GSTM1 coding for the functional antioxidant enzyme (Tables 4 and 5). It is unexpected that
the oxidized glutathione would be unaffected by GSTM1 polymorphism when 8-oxo-dG
levels are reduced. A possible explanation for this finding lies in cooperation of enzymes
contributing to the cellular redox system. Individuals with null genotype of GSTM1 have
increased concentrations of compensatory antioxidant enzymes after exposure to oxidative
stress; in particular, activity of superoxide dismutase has been reported to be significantly
higher in individuals with null vs. GSTM1 gene after exposure to ozone [55]. Further
research is needed to confirm whether compensatory up regulation of this nature could be a
factor in the antioxidant status of individuals with null GSTM1 gene.
Apart from the effect of HIV, other variables also contribute significantly to oxidative stress
in HIV-infected individuals, including co-infection with hepatitis C and alcohol use. Dual
infection of HIV and HCV has become a leading cause of mortality among HIV infected
patients, and has been associated with increased levels of oxidative stress [18,56]. Alcohol
use generates oxidative damage in pathways similar to those associated with HIV, leading to
a greater combined effect than either risk factor alone [57]. The analysis of the HIV/HCV
co-infected and alcohol-drinking sub-cohorts in this study revealed similar effects on
oxidative stress and disease progression, with some notable exceptions. Although HIV viral
load remained significantly lower in individuals with the non-null GSTM1 vs. the null gene
in both sub-cohorts, neither group had significant genotype association with CD4 cell count.
This was likely caused by the smaller sample size of the sub-cohort groups, which no longer
had sufficient power to examine the relationship. Another novel finding of the sub-cohorts
compared to the full sample was the elevated levels of oxidized glutathione observed in the
HIV/HCV co-infected and those who consumed alcohol with the GSTM1 genotype status
coding for the functional antioxidant enzyme. These results may indicate the proposed
compensatory upregulation of coexisting antioxidant enzymes.
Activities of electron transport chain enzymes Complex I and IV are distinct indicators of
mitochondrial toxicity and dysfunction of oxidative phosphorylation [58]. The lower
Complex I enzyme activity along with significantly lower apoptosis in the HIV/HCV co-
infected participants with the GSTM1 genotype coding for the functional antioxidant
enzyme are consistent with the reports of differential regulation of the two complexes in
times of acute HIV infection and induction of apoptosis [59]. This suggests that those
individuals possessing the null mutation may be more susceptible to dysregulation of
oxidative phosphorylation by HIV, and ultimately T-cell apoptosis, compared to those with
the GSTM1 coding for the functional antioxidant enzyme.
Analyses to characterize the potential impact of the GSTM1 genotype on disease
progression and oxidative stress among those who are HIV/HCV co-infected and those who
consumed alcohol revealed modulated effects of the GSTM1 null-allele polymorphism.
While both HIV/HCV co-infection and alcohol consumption increased hepatic apoptosis,
having the GSTM1 null genotype increased oxidative stress particularly for alcohol
consumption.
The findings of this study show that null-allele polymorphism of GSTM1 has a significant
effect on oxidative stress and antioxidant status during HIV infection. Furthermore, this
effect is clinically detectable in its impact on CD4 cell count and HIV viral load. This
investigation represents only an initial assessment of the polymorphism’s role in HIV
infection, and further research will be critical to discerning the mechanism involved and any
potential therapeutic applications.
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A comparison of the activities of antioxidant enzymes coexisting alongside GSTs, in relation
to the GSTM1 genotype, will be needed to elucidate variation in levels of oxidative stress
biomarkers. Additionally, genotyping techniques with the ability to differentiate between
individuals carrying one or two copies of the GSTM1 gene would allow for more detailed
analysis of the polymorphism’s effects. If the role of this polymorphism in HIV infection is
further clarified, there is potential for GSTM1 to be used as a clinical marker to quantify risk
for oxidative damage in HIV-infected individuals, possibly serving as a criterion to
demonstrate a need for antioxidant supplementation. Further research will be needed to
explore these possibilities, and to unfold the pathways that control oxidative stress and HIV
disease progression.
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Figure 1.
Frequency of the Functional (Non-Null) Genotype by Ethnicity.
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Table 1
Population Characteristics.
Characteristic
Overall
(n = 129)
[mean ± SD]
GSTM1 Null
(n = 53)
[mean ± SD]
GSTM1 Non-Null
(n = 76)
[mean ± SD]
P-value
Male [% (n)] 55.81% (72) 52.83% (28) 57.89% (44) 0.572
Age (years) 48.32 ± 6.31 48.53 ± 6.78 48.17 ± 6.00 0.755
CD4 count (cells/uL) 591 ± 414 592 ± 505 590 ± 295 0.988
HIV viral load (copies/mL) 16,416 ± 94,636 34,633 ± 149,550 4,769 ± 16,098 0.222
Monthly Income ($) 469.33 ± 484.33 450.10 ± 494.60 482.30 ± 480.90 0.741
Education (grades) 11.76 ± 2.15 11.70 ± 2.05 11.81 ± 2.23 0.809
BMI (kg/m2) 28.29 ± 5.29 28.99 ± 5.22 27.81 ± 5.31 0.217
Waist/Hip Ratio 0.91 ± 0.07 0.92 ± 0.07 0.91 ± 0.07 0.651
HIV/HCV co-infected [%(n)] 44.96% (58) 50.94% (27) 40.79% (31) 0.258
Receiving ART [%(n)] 89.92% (116) 92.45% (49) 88.16% (67) 0.429
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Table 2
Effects of the Functional (Non-Null) GSTM1 Genotype on HIV Disease Progression.
VariableMean ± SD Parameter Estimate Standard Error T-value P-value
HIV viral load (copies/mL) 16,416 ± 94,636 −0.536 0.223 −2.41 0.018*
CD4 cell count (cells/uL) 591 ± 414 3.480 1.618 2.15 0.034*
*
Indicates statistically significant results. P-value associated with linear regression analysis.
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